TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3402181

Group type: EXPERIMENTAL
Intervention: Continuous infusion of metoclopramide (loading dose of 3 mg/kg followed by 0.5 mg/kg/hr for 12 hours)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bolus doses of metoclopramide (2 mg/kg added to each bolus dose)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Continuous infusion of metoclopramide (placebo of 5% dextrose injection)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bolus doses of metoclopramide (placebo of 5% dextrose injection)
Number of subjects: 27
Study: 29658353

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5‐mg intravenous injection, administered 1 week postoperatively)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (administered 1 week postoperatively)
Number of subjects: 113
Study: 29141679

Group type: EXPERIMENTAL
Intervention: Intramuscular oxytocin (10 IU in 1 mL)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (10 IU in 1 mL given slowly over 1 min)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo intravenous injection (1 mL 0.9% saline given slowly)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo intramuscular injection (1 mL 0.9% saline)
Number of subjects: 1000
Study: 26465983

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 863

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study: 23117133

Group type: EXPERIMENTAL
Intervention: Pre-LH surge
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-LH surge
Number of subjects: 25

Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 25
Study: 21997940

Group type: EXPERIMENTAL
Intervention: Depilatory cream
Number of subjects: 165

Group type: COMPARATOR
Intervention: Razor shaving
Number of subjects: 165
Study: 18435231

Group type: EXPERIMENTAL
Intervention: Oral health education by health visitor, including dental health advice, toothbrush and toothpaste with 440 ppm fluoride, provided during home visits at ages 8 months and 20 months.
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group received usual care from health visitors.
Number of subjects: 501
Study: 16586358

Group type: EXPERIMENTAL
Intervention: Trivalent baculovirus-expressed HA vaccine at 45 microg
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Trivalent baculovirus-expressed HA vaccine at 135 microg
Number of subjects: 399

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 399
Study: 12719743

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Distraction intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 10742158

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study: 8816723

Group type: EXPERIMENTAL
Intervention: Pravastatin 20mg at night
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 1330019

Group type: EXPERIMENTAL
Intervention: Cholera toxin (15 micrograms or 25 micrograms) administered into a 'closed' jejunal segment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholera toxin administered by mouth with sodium bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholera toxin delivered directly into an 'open' jejunal segment
Number of subjects: 0
Study: 4043682

Group type: EXPERIMENTAL
Intervention: 35-cm flexible sigmoidoscope
Number of subjects: 258

Group type: COMPARATOR
Intervention: 60-cm flexible sigmoidoscope
Number of subjects: 258
Study: 29670343

Group type: EXPERIMENTAL
Intervention: Periodized exercise intervention (N=15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-periodized exercise intervention (N=13)
Number of subjects: 28
Study: 27598679

Group type: EXPERIMENTAL
Intervention: Transvenous neurostimulation (treatment group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No stimulation (control group)
Number of subjects: 151
Study: 24247616

Group type: EXPERIMENTAL
Intervention: Varespladib (500 mg daily for 16 weeks)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Varespladib
Number of subjects: 5145
Study: 23270291

Group type: EXPERIMENTAL
Intervention: Xeno® III - sandblasting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AdheSE - sandblasting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AdheSE - grinding
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AdheSE - cleaned only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Xeno® III - cleaned only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Xeno® III - grinding
Number of subjects: 30
Study: 20537812

Group type: EXPERIMENTAL
Intervention: memantine 20mg bid (N=39)
Number of subjects: 112

Group type: COMPARATOR
Intervention: placebo (N=42)
Number of subjects: 112

Group type: COMPARATOR
Intervention: lead-in period (high-value voucher contingency management)
Number of subjects: 112
Study: 18675711

Group type: EXPERIMENTAL
Intervention: CAH patients with severe form of the disease
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CAH patients with milder forms of the disorder
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Advanced bone age (indicator of long-term childhood exposure to testosterone)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 54
Study: 15902990

Group type: EXPERIMENTAL
Intervention: 0.3 g/kg of NH4Cl (ACD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg of Na+HCO3‐ and 0.2 g/kg of sodium citrate (ALK)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (calcium carbonate) (PLAC)
Number of subjects: 12
Study: 11487536

Group type: EXPERIMENTAL
Intervention: Natalizumab (3 mg/kg infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9620569

Group type: EXPERIMENTAL
Intervention: Paediatric assessment
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Health visitor questionnaire
Number of subjects: 776

Group type: COMPARATOR
Intervention: Paediatric assessment vs Health visitor questionnaire
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Trial endpoint
Number of subjects: 776
Study: 8026943

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 10
Study: 2692553

Group type: EXPERIMENTAL
Intervention: Behavioural control procedures
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cognitive control methods (distraction)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untreated control subjects
Number of subjects: 27
Study: 31994643

Group type: EXPERIMENTAL
Intervention: 5% naproxen patches
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 30
Study: 26997317

Group type: EXPERIMENTAL
Intervention: Happy Being Me Co‐educational intervention delivered in single-sex classes (n=74)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Happy Being Me Co‐educational intervention delivered in co-educational classes (n=73)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No-intervention control group (n=53)
Number of subjects: 200
Study: 24990390

Group type: EXPERIMENTAL
Intervention: low protein diet + prebiotic + probiotic supplementation (N=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: low protein diet only (N=12)
Number of subjects: 24
Study: 24996984

Group type: EXPERIMENTAL
Intervention: BAL-directed therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 21903347

Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups (RMCs)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 446
Study: 18633127

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/day (stage 1)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Benzbromarone 100 mg/day (stage 1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/day (stage 2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Benzbromarone 200 mg/day (stage 2)
Number of subjects: 65
Study: 17353072

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 15155715

Group type: EXPERIMENTAL
Intervention: Endurance-trained (ET) subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nontrained (NT) women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups after a 90-min exercise bout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance-trained (ET) men
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontrained (NT) subjects
Number of subjects: 0
Study: 11250852

Group type: EXPERIMENTAL
Intervention: Individual educational visits
Number of subjects: 240000

Group type: EXPERIMENTAL
Intervention: Group educational visits
Number of subjects: 240000

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 240000
Study: 9498508

Group type: EXPERIMENTAL
Intervention: Insulin treatment (25 to 49 U/h for 7 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7988265

Group type: EXPERIMENTAL
Intervention: Intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,200 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intrapleural chemotherapy with cisplatin and cytarabine
Number of subjects: 46
Study: 2919139

Group type: EXPERIMENTAL
Intervention: Bovine surfactant (surfactant TA, Tokyo Tanabe Co, Tokyo)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bovine surfactant mixed with technetium‐99m sulfur colloid
Number of subjects: 41
Study: 29710099

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education combined with cognition-targeted motor control training
Number of subjects: 120
Study: 28145413

Group type: EXPERIMENTAL
Intervention: Lovaza (omega-3 preparation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study: 26130341

Group type: EXPERIMENTAL
Intervention: Cobalt-chrome (CoCr) femoral head and highly cross-linked polyethylene (XLPE) liner
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Oxidised zirconium (OxZi) femoral head and XLPE liner
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Oxidised zirconium (OxZi) femoral head and ultra-high molecular weight polyethylene (UHMWPE) liner
Number of subjects: 368

Group type: COMPARATOR
Intervention: Cobalt-chrome (CoCr) with XLPE vs OxZi with XLPE
Number of subjects: 368
Study: 23446892

Group type: EXPERIMENTAL
Intervention: Plasma trans 18:2 (linoleic acid) fatty acids
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Plasma trans 16:1 and 18:1 fatty acids
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Dietary trans fats
Number of subjects: 1576
Study: 21054216

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) plus current NRTI backbone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuation of current regimen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 20
Study: 20043831

Group type: EXPERIMENTAL
Intervention: Daily activity monitoring and distance counselling (12 months)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 1100
Study: 17295588

Group type: EXPERIMENTAL
Intervention: Nicotine (0.60 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Expectancy (no nicotine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Expectancy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nicotine (0.60 mg) and Expectancy
Number of subjects: 120
Study: 15582071

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK with Zyoptix 3.1 system
Number of subjects: 97
Study: 11506058

Group type: EXPERIMENTAL
Intervention: 3.0 g/day phytosterols
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 6.0 g/day phytosterols
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 9.0 g/day phytosterols
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.0 g/day phytosterols (control)
Number of subjects: 84
Study: 8738379

Group type: EXPERIMENTAL
Intervention: Valid trials with location cues indicating the target location
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Invalid trials with location cues indicating the opposite location
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Peripheral cue in gap condition (experiment 1)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Peripheral cue in overlap condition (experiment 2)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Central cue without visual stimulation at peripheral location (experiment 3)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Cue-elicited saccades in response to the cue with target at opposite location
Number of subjects: 1280
Study: 2105242

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (3.75 mg IM every 4 weeks for four injections)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (IM every 4 weeks for four injections)
Number of subjects: 18
Study: 7419983

Group type: EXPERIMENTAL
Intervention: Hypothesis-generating group (36 subjects)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Hypothesis-testing group (18 subjects)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Model parameters (production rate, pool sizes)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Model parameters (cholesterol mass)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Model parameters (pool sizes)
Number of subjects: 54
Study: 31561712

Group type: EXPERIMENTAL
Intervention: Preventure
Number of subjects: 947

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 947

Group type: COMPARATOR
Intervention: Climate Schools
Number of subjects: 947

Group type: COMPARATOR
Intervention: Combined Climate Schools and Preventure (CAP)
Number of subjects: 947
Study: 30545915

Group type: EXPERIMENTAL
Intervention: anti-IL-1β Abs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti-PD-1 Abs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti-IL-1β Abs followed by anti-PD-1 Abs
Number of subjects: 0
Study: 27060991

Group type: EXPERIMENTAL
Intervention: Combination therapy (CT) with silodosin at 8 mg/day and propiverine at 20 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: α1-blocker monotherapy (MT) with silodosin at 8 mg/day
Number of subjects: 120
Study: 25702095

Group type: EXPERIMENTAL
Intervention: 15 mg/kg tranexamic acid (TXA) in 100 mL normal saline solution
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 92
Study: 25639139

Group type: EXPERIMENTAL
Intervention: Meat biscuits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soybean biscuits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wheat biscuit (control)
Number of subjects: 0
Study: 22711350

Group type: EXPERIMENTAL
Intervention: EPB‐348 2,000 mg once‐daily
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: EPB‐348 3,000 mg once‐daily
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: EPB‐348 1,000 mg once‐daily
Number of subjects: 373

Group type: COMPARATOR
Intervention: valacyclovir 1,000 mg 3‐times daily
Number of subjects: 373
Study: 20048210

Group type: EXPERIMENTAL
Intervention: varenicline (1 mg twice daily)
Number of subjects: 714

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 714
Study: 18478182

Group type: EXPERIMENTAL
Intervention: nizatidine (300 mg a day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: famotidine (40 mg a day; control)
Number of subjects: 27
Study: 16317825

Group type: EXPERIMENTAL
Intervention: THC:CBD spray (Sativex)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 11846320

Group type: EXPERIMENTAL
Intervention: Third extrastimulus introduced during programmed ventricular stimulation (protocol A)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Third extrastimulus introduced early (protocol B)
Number of subjects: 94
Study: 10066995

Group type: EXPERIMENTAL
Intervention: Treatment for depression over 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posttreatment depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 18-month follow-up
Number of subjects: 0
Study: 8773419

Group type: EXPERIMENTAL
Intervention: Lea's Shield with spermicide
Number of subjects: 185

Group type: COMPARATOR
Intervention: Lea's Shield without spermicide
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Lea's Shield (both groups)
Number of subjects: 185
Study: 1611645

Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg thrice daily)
Number of subjects: 579
Study: 6360413

Group type: EXPERIMENTAL
Intervention: Ethmozine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31001997

Group type: COMPARATOR
Intervention: Patients reporting no angina (62.3%)
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Younger age, worse preoperative SAQ angina frequency score, smoking, diabetes mellitus, and pre‐CABG depression
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization of the left anterior descending (LAD) territory
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Residual major coronary artery stenosis of ≥70%
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Graft occlusions, incomplete revascularization of non‐LAD territories, and ≥70% lesions in nonrevascularized native coronary arteries
Number of subjects: 1258
Study: 29178239

Group type: EXPERIMENTAL
Intervention: Communities Mobilizing for Change on Alcohol (CMCA) intervention
Number of subjects: 1399
Study: 26872880

Group type: EXPERIMENTAL
Intervention: 6 session alcohol harm reduction intervention
Number of subjects: 818

Group type: COMPARATOR
Intervention: 6 session non-alcohol related nutrition intervention
Number of subjects: 818
Study: 24352294

Group type: EXPERIMENTAL
Intervention: Short sleep (4 hours per night)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Habitual sleep (8 hours per night)
Number of subjects: 10
Study: 21195592

Group type: EXPERIMENTAL
Intervention: Whole grain wheat sourdough bread (162.5 g)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Refined white bread (168.8 g)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole grain wheat sourdough bread
Number of subjects: 28

Group type: COMPARATOR
Intervention: Refined white bread
Number of subjects: 28
Study: 20718545

Group type: EXPERIMENTAL
Intervention: Prayer for the partner over a 6-week period
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Daily prayer for 4 weeks
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Prayer for the partner for 4 weeks
Number of subjects: 375

Group type: COMPARATOR
Intervention: Daily positive thoughts about the partner or a neutral activity
Number of subjects: 375
Study: 17701114

Group type: EXPERIMENTAL
Intervention: Multidimensional advice session in small groups at a geriatric centre
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Multidimensional advice at the seniors home through one member of the interdisciplinary team
Number of subjects: 804

Group type: COMPARATOR
Intervention: Refusal to participate in health promoting programmes
Number of subjects: 804
Study: 16078132

Group type: EXPERIMENTAL
Intervention: Sum of inverse Gaussian functions for hydromorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sum of inverse Gaussian functions for veralipride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sum of inverse Gaussian functions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonparametric method using linear splines
Number of subjects: 0
Study: 11923036

Group type: EXPERIMENTAL
Intervention: Baseline serum concentrations of sICAM‐1 in cases (n = 136)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Baseline serum concentrations of sICAM‐1 in controls (n = 136)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Each 100 ng/ml increase in sICAM‐1 concentration
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: sICAM‐1 concentration in the highest quartile (>394 ng/ml)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: After adding fibrinogen to the multivariate model
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: After adding total white blood cell count to the multivariate model
Number of subjects: 272
Study: 9534836

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 8548947

Group type: EXPERIMENTAL
Intervention: Hexarelin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 6

Group type: COMPARATOR
Intervention: rhGH
Number of subjects: 6
Study: 2082308

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 90 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Morphine sulfate 10 mg
Number of subjects: 18
Study: 476704

Group type: COMPARATOR
Intervention: Cyclophosphamide plus prednisone (CP)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus BCNU plus prednisone (CBP)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Both CP and CBP
Number of subjects: 89
Study: 31888371

Group type: EXPERIMENTAL
Intervention: Woodcast
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fibreglass cast
Number of subjects: 120
Study: 31125325

Group type: EXPERIMENTAL
Intervention: Functional Strength Training (FST)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Traditional Strength Training (TST)
Number of subjects: 144
Study: 28103714

Group type: EXPERIMENTAL
Intervention: Gaze‐contingent music reward therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study: 26529006

Group type: EXPERIMENTAL
Intervention: Formula enriched with Metlin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula enriched with Metlos
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infant formula only (control)
Number of subjects: 0
Study: 23490599

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 0